{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:39:25Z","timestamp":1775155165379,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mount Sinai OBGYN Department Research Grant","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["MOP142364 and PJT162328"],"award-info":[{"award-number":["MOP142364 and PJT162328"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL\/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa\/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS\/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-021-00895-w","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:07:03Z","timestamp":1637042823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-9585","authenticated-orcid":false,"given":"Mitchell","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kollara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"895_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"895_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2012.06.033","volume":"127","author":"C Maringe","year":"2012","unstructured":"Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012;127:75\u201382.","journal-title":"Gynecol Oncol"},{"key":"895_CR3","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460\u201373.","journal-title":"J Clin Oncol"},{"key":"895_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","volume":"103","author":"DS Chi","year":"2006","unstructured":"Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559\u201364.","journal-title":"Gynecol Oncol"},{"key":"895_CR5","doi-asserted-by":"crossref","unstructured":"Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011(8):CD007565.","DOI":"10.1002\/14651858.CD007565.pub2"},{"key":"895_CR6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","volume":"26","author":"SJ Chang","year":"2015","unstructured":"Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015;26:336\u201342.","journal-title":"J Gynecol Oncol"},{"key":"895_CR7","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19:1680\u20137.","journal-title":"Lancet Oncol"},{"key":"895_CR8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"895_CR9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.1997.175","volume":"75","author":"AE Bogden","year":"1997","unstructured":"Bogden AE, Moreau JP, Eden PA. Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br J Cancer. 1997;75:1021\u20137.","journal-title":"Br J Cancer"},{"key":"895_CR10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/sj.bjc.6690223","volume":"79","author":"R Abramovitch","year":"1999","unstructured":"Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 1999;79:1392\u20138.","journal-title":"Br J Cancer"},{"key":"895_CR11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdn386","volume":"19","author":"R Demicheli","year":"2008","unstructured":"Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19:1821\u20138.","journal-title":"Ann Oncol"},{"key":"895_CR12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7","volume":"45","author":"PH Lange","year":"1980","unstructured":"Lange PH, Hekmat K, Bosl G, Kennedy BJ, Fraley EE. Acclerated growth of testicular cancer after cytoreductive surgery. Cancer. 1980;45:1498\u2013506.","journal-title":"Cancer"},{"key":"895_CR13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers2020305","volume":"2","author":"M Retsky","year":"2010","unstructured":"Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I. Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth? Cancers (Basel). 2010;2:305\u201337.","journal-title":"Cancers (Basel)"},{"key":"895_CR14","first-page":"309","volume":"28","author":"EE Tyzzer","year":"1913","unstructured":"Tyzzer EE. Factors in the production and growth of tumor metastases. J Med Res. 1913;28:309\u201321.","journal-title":"J Med Res"},{"key":"895_CR15","first-page":"1749","volume":"60","author":"L Simpson-Herren","year":"1976","unstructured":"Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976;60:1749\u201360.","journal-title":"Cancer Treat Rep"},{"key":"895_CR16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(03)14112-8","volume":"362","author":"E Tagliabue","year":"2003","unstructured":"Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet. 2003;362:527\u201333.","journal-title":"Lancet"},{"key":"895_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13048-018-0428-6","volume":"11","author":"Y Lee","year":"2018","unstructured":"Lee Y, Kollara A, May T, Brown TJ. Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. J Ovarian Res. 2018;11:56.","journal-title":"J Ovarian Res"},{"key":"895_CR18","first-page":"3861","volume":"39","author":"N Gunduz","year":"1979","unstructured":"Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39:3861\u20135.","journal-title":"Cancer Res"},{"key":"895_CR19","first-page":"1996","volume":"49","author":"B Fisher","year":"1989","unstructured":"Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49:1996\u20132001.","journal-title":"Cancer Res"},{"key":"895_CR20","first-page":"1488","volume":"43","author":"B Fisher","year":"1983","unstructured":"Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43:1488\u201392.","journal-title":"Cancer Res"},{"key":"895_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-018-9896-8","volume":"35","author":"M Alieva","year":"2018","unstructured":"Alieva M, van Rheenen J, Broekman MLD. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis. 2018;35:319\u201331.","journal-title":"Clin Exp Metastasis"},{"key":"895_CR22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nm0295-149","volume":"1","author":"L Holmgren","year":"1995","unstructured":"Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149\u201353.","journal-title":"Nat Med"},{"key":"895_CR23","first-page":"273","volume":"79","author":"MS O'Reilly","year":"1997","unstructured":"O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS. 1997;79:273\u201394.","journal-title":"EXS"},{"key":"895_CR24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2007.10.035","volume":"108","author":"J Greenaway","year":"2008","unstructured":"Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol. 2008;108:385\u201394.","journal-title":"Gynecol Oncol"},{"key":"895_CR25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585\u201391.","journal-title":"Carcinogenesis"},{"key":"895_CR26","doi-asserted-by":"crossref","first-page":"Abstr 5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","volume":"35","author":"MC Lim","year":"2017","unstructured":"Lim MC, Chang S-J, Yoo HJ, Nam B-H, Bristow R, Park S-Y. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. Journal of Clinical Oncology. 2017;35:Abstr 5520.","journal-title":"Journal of Clinical Oncology"},{"key":"895_CR27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med"},{"key":"895_CR28","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","volume":"34","author":"LA Meyer","year":"2016","unstructured":"Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34:3854\u201363.","journal-title":"J Clin Oncol"},{"key":"895_CR29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00404-009-1121-1","volume":"281","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Eno ML, Im DD, Rosenshein NB. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet. 2010;281:325\u20138.","journal-title":"Arch Gynecol Obstet"},{"key":"895_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ijgo.12653","volume":"143","author":"YY Lee","year":"2018","unstructured":"Lee YY, Lee JW, Lu L, Xu W, Kollara A, Brown T, et al. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynaecol Obstet. 2018;143:325\u201332.","journal-title":"Int J Gynaecol Obstet"},{"key":"895_CR31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/00016340902814559","volume":"88","author":"E Larsen","year":"2009","unstructured":"Larsen E, Blaakaer J. Epithelial ovarian cancer: does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? Acta Obstet Gynecol Scand. 2009;88:373\u20137.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"895_CR32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","volume":"49","author":"S Mahner","year":"2013","unstructured":"Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49:142\u20139.","journal-title":"Eur J Cancer"},{"key":"895_CR33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","volume":"131","author":"G Hofstetter","year":"2013","unstructured":"Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131:15\u201320.","journal-title":"Gynecol Oncol"},{"key":"895_CR34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2017.11.023","volume":"148","author":"YJ Lee","year":"2018","unstructured":"Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim S, et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecol Oncol. 2018;148:62\u20137.","journal-title":"Gynecol Oncol"},{"key":"895_CR35","doi-asserted-by":"crossref","unstructured":"Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, Weinberg RA. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 2018;10(436):eaan3464.","DOI":"10.1126\/scitranslmed.aan3464"},{"key":"895_CR36","doi-asserted-by":"publisher","unstructured":"Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, Albers KB, Yamaguchi N, Narke D, Schlegel M, Sharma M, Shanley LC, Barrett TJ, Rahman K, Mezzano V, Fisher EA, Park DS, Newman JD, Quail DF, Nelson ER, Caan BJ, Jones LW, Moore KJ. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med. 2020;26(9):1452\u20138. https:\/\/doi.org\/10.1038\/s41591-020-0964-7.","DOI":"10.1038\/s41591-020-0964-7"},{"key":"895_CR37","unstructured":"Lee Y-Y, Kollara A, Shathasivam P, Yeo SC, Burt B, Hollingsworth J, Pavlovic T, Brown T, May T. Impact of wound healing on ovarian cancer progression and sensitivity to platinum-based agents: a pilot study using a snygeneic orthotopic mouse model. 2017; Ottawa"},{"key":"895_CR38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ctm2.24","volume":"10","author":"F Tang","year":"2020","unstructured":"Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med. 2020;10:199\u2013223.","journal-title":"Clin Transl Med"},{"key":"895_CR39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336.","journal-title":"Lancet Oncol"},{"key":"895_CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.01.009","volume":"129","author":"JA Rauh-Hain","year":"2013","unstructured":"Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129:63\u20138.","journal-title":"Gynecol Oncol"},{"key":"895_CR41","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.21873\/anticanres.14248","volume":"40","author":"AW Ekmann-Gade","year":"2020","unstructured":"Ekmann-Gade AW, Hogdall CK, Engelholm SA, Fago-Olsen CL. Neoadjuvant chemotherapy reduces the treatment-free interval after first-line treatment in patients with advanced ovarian cancer. Anticancer Res. 2020;40:2765\u201370.","journal-title":"Anticancer Res"},{"key":"895_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2012.05.021","volume":"324","author":"P Chiarella","year":"2012","unstructured":"Chiarella P, Bruzzo J, Meiss RP, Ruggiero RA. Concomitant tumor resistance. Cancer Lett. 2012;324:133\u201341.","journal-title":"Cancer Lett"},{"key":"895_CR43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrclinonc.2014.224","volume":"12","author":"M Horowitz","year":"2015","unstructured":"Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015;12:213\u201326.","journal-title":"Nat Rev Clin Oncol"},{"key":"895_CR44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/SLA.0b013e3181efc635","volume":"252","author":"O Al-Sahaf","year":"2010","unstructured":"Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg. 2010;252:1037\u201343.","journal-title":"Ann Surg"},{"key":"895_CR45","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","volume":"17","author":"WJ Aston","year":"2017","unstructured":"Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017;17:684.","journal-title":"BMC Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00895-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:08:18Z","timestamp":1637042898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00895-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00895-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-337405\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the University of Toronto Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}